Negev Capital — Full Portfolio
3 tracked investments · listed companies and verified rows first
Delix Therapeutics develops third-generation, non-hallucinogenic neuroplastogens for people with neurological conditions, using a discovery platform to identify novel compounds.
BiotechDigital HealthMedical Devices
Co-investorsArtis VenturesCasa Verde CapitalNoeticOMX VenturesPsyMed VenturesRA Capital+6 more
Gilgamesh Pharmaceutical develops novel chemical entities for psychiatric disorders using medicinal chemistry and AI-powered translational platforms to design rapid-acting therapies targeting neurobiological mechanisms rather than symptom management.
AI & Machine LearningBiotechDigital HealthHealthtechNew York City, US
Jonathan Sporn(Founder)inAndrew Kruegel(Founder)inDalibor Sames(Founder)inJONATHAN SPORN(Founder)inAndrew Kruegel, Ph.D.(Executive Officer)Jonathan Sporn, M.D.(President and Chief Executive Officer)in
Co-investorsAera VCFrontera Technology VenturesFrontier Path VCJames Beshara FundJLSMagnetic Ventures+9 more
Mindstate Design Labs is a clinical-stage drug development company that uses AI to map the biological basis of emotion and cognition, synthesizing psychedelic phenomenology and biochemical data to design pharmaceutical compounds that induce specific therapeutic emotional and cognitive states for mental health treatment.
AI & Machine LearningBiotechHealthtechMental HealthSan Francisco, US
Dillan DiNardo(Founder/CEO)inTom Ray(Founder)in
BoardRand Hindi(Director)in
Co-investorsImmeasurableMetaplanetPsyMed VenturesY CombinatorDay One VenturesInitialized Capital+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.